[go: up one dir, main page]

PE20080894A1 - CHROMAN DERIVATIVES AS AGONISTS OF SEROTONIN 2C (5-HT2C) RECEPTORS - Google Patents

CHROMAN DERIVATIVES AS AGONISTS OF SEROTONIN 2C (5-HT2C) RECEPTORS

Info

Publication number
PE20080894A1
PE20080894A1 PE2007001447A PE2007001447A PE20080894A1 PE 20080894 A1 PE20080894 A1 PE 20080894A1 PE 2007001447 A PE2007001447 A PE 2007001447A PE 2007001447 A PE2007001447 A PE 2007001447A PE 20080894 A1 PE20080894 A1 PE 20080894A1
Authority
PE
Peru
Prior art keywords
ht2c
serotonin
agonists
receptors
compounds
Prior art date
Application number
PE2007001447A
Other languages
Spanish (es)
Inventor
Gary Paul Stack
William Demaio
John Chuck Lem Erve
Karthick Vishwanathan
Jianyao Wang
Sarvesh Vashishtha
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080894A1 publication Critical patent/PE20080894A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CROMANO DE FORMULA (I) DONDE ----- ES UN ENLACE SIMPLE O DOBLE; R1 ES H, ALQUILO INFERIOR(C1-C4), S(O)2OH O C(O)R, DONDE R ES H O ALQUILO INFERIOR(C1-C4) OPCIONALMENTE SUSTITUIDO CON OH; A ES N(H), N(OH) U O; R2 ES H U OH; R3 Y R4 SON CADA UNO H, HALOGENO, METILO, METOXI U OH; Ra, Ra', Rb Y Rb' SON CADA UNO H U OH; Ra Y Rb, O Ra' Y Rb' SE TOMAN JUNTO CON EL C AL QUE ESTAN UNIDOS PARA FORMAR UN CARBONILO; Rc Y Rd SON CADA UNO H U OH, O SE TOMAN JUNTO CON EL C AL QUE ESTAN UNIDOS PARA FORMAR UN CARBONILO; Re ES H U OH; Rx ES H, HALOGENO, CF3 O ALQUILO INFERIOR(C1-C4); Ry ES H U OH; m ES DE 1 A 3; n ES 1 O 2. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES DE SEROTONINA 2C (5-HT2C) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, OBESIDAD, TRANSTORNO BIPOLAR, TRANSTORNO DEPRESIVOREFERS TO CHROMAN DERIVATIVE COMPOUNDS OF FORMULA (I) WHERE ----- IS A SINGLE OR DOUBLE LINK; R1 IS H, LOWER ALKYL (C1-C4), S (O) 2OH OR C (O) R, WHERE R IS H OR LOWER ALKYL (C1-C4) OPTIONALLY SUBSTITUTED WITH OH; A IS N (H), N (OH) U O; R2 IS H U OH; R3 AND R4 ARE EACH H, HALOGEN, METHYL, METHOXY, OR OH; Ra, Ra ', Rb, and Rb' ARE EACH H OR OH; Ra AND Rb, OR Ra 'AND Rb' ARE TAKEN TOGETHER WITH THE C TO WHICH THEY ARE UNITED TO FORM A CARBONYL; Rc AND Rd ARE EACH H U OH, OR ARE TAKEN TOGETHER WITH THE C TO WHICH THEY ARE UNITED TO FORM A CARBONYL; Re IS H U OH; Rx IS H, HALOGEN, CF3, OR LOWER ALKYL (C1-C4); Ry ES H U OH; m IS 1 TO 3; n IS 1 OR 2. PREFERRED COMPOUNDS ARE THE COMPOUNDS OF FORMULA (i), (ii), AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE AGONISTS OF SEROTONIN 2C RECEPTORS (5-HT2C), BEING USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, OBESITY, BIPOLAR DISORDER, DEPRESSIVE TRANSFORMATION

PE2007001447A 2006-10-24 2007-10-24 CHROMAN DERIVATIVES AS AGONISTS OF SEROTONIN 2C (5-HT2C) RECEPTORS PE20080894A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85385506P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
PE20080894A1 true PE20080894A1 (en) 2008-08-28

Family

ID=39168425

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001447A PE20080894A1 (en) 2006-10-24 2007-10-24 CHROMAN DERIVATIVES AS AGONISTS OF SEROTONIN 2C (5-HT2C) RECEPTORS

Country Status (5)

Country Link
AR (1) AR063375A1 (en)
CL (1) CL2007003043A1 (en)
PE (1) PE20080894A1 (en)
TW (1) TW200823186A (en)
WO (1) WO2008052087A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520051B2 (en) 2007-11-15 2014-06-11 武田薬品工業株式会社 Condensed pyridine derivatives and uses thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3878447A1 (en) 2020-03-11 2021-09-15 InterAx Biotech AG Beta adrenergic receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135474A1 (en) * 1991-10-28 1993-04-29 Bayer Ag 2-AMINOMETHYL-chromans
KR100330696B1 (en) * 1993-08-19 2002-10-04 얀센 파마슈티카 엔.브이. Vasoconstrictive dihydrobenzopyran derivatives
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
JP2008538576A (en) * 2005-04-22 2008-10-30 ワイス Chroman and chromene derivatives and uses thereof

Also Published As

Publication number Publication date
CL2007003043A1 (en) 2008-05-30
TW200823186A (en) 2008-06-01
AR063375A1 (en) 2009-01-28
WO2008052087A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
PE20061298A1 (en) DIHYDROBENZOFURAN-DERIVED COMPOUNDS AS AGONISTS OF THE SEROTONIN 5-HT2C RECEPTOR
CR9459A (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME
DOP2006000076A (en) CYCLOPENTAPIRIDINE AND TETRAHYDROQUINOLINE DERIVATIVES
AR078163A1 (en) USE OF AMINODIHYDROTIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES
AR058124A1 (en) FTALAZINONA DERIVATIVES AS PARP-1 INHIBITORS
PE20091621A1 (en) AMINE DERIVATIVES AS MODULATORS OF TLR ACTIVITY AND COMPOSITIONS CONTAINING THEM
PE20130155A1 (en) ARYLETINYL DERIVATIVES
UY28936A1 (en) GROUP OF BENZOIL-AMINO-HETEROCICLILO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL FOR TREATMENT OF GLUCOQUINASE-AIDED DISEASES (GQ)
AR056979A1 (en) DERIVATIVES OF DIHYDROBENZOFURANS AND USES OF THE SAME
GT200600166A (en) CHROMAN AND CHROME DERIVATIVES AND USES OF THE SAME
AR054024A1 (en) PIRIDINE DERIVATIVES -3- CARBOXAMIDE AS INVESTED AGONISTS OF CB1
AR065822A1 (en) THIAZOLIDINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS AND USES AS ANTAGONISTS OF THE OREXINE RECEIVER
AR067662A1 (en) BENZO DERIVATIVES [D] ISOXAZOL-3-IL-PIPERIDINE, MEDICINES CONTAINING THERAPEUTIC USES AND DISEASES FOR DISEASES ASSOCIATED WITH THE NERVOUS SYSTEM.
PE20091204A1 (en) 2-AMINOQUINOLINE DERIVATIVES AS ANTAGONISTS OF THE 5-HT5A RECEPTOR
ECSP099216A (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CR20110484A (en) NEW BENZOTIAZEPINAS DERIVATIVES ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR060535A1 (en) PIRIDO-PIRIDAZINONAS AND FTALAZINONAS AS DUAL ANTAGONISTS OF THE H1 AND H3 RECEPTORS OF HISTAMINE
DOP2006000202A (en) CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC RECEIVER
PE20080894A1 (en) CHROMAN DERIVATIVES AS AGONISTS OF SEROTONIN 2C (5-HT2C) RECEPTORS
PE20091450A1 (en) INHIBITORS OF STEAROIL-CoA-DESATURASE
AR070485A1 (en) COMPOUNDS DERIVED FROM AZETIDINES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
ECSP088257A (en) AMIDA DERIVATIVES
AR067873A1 (en) BENZOIL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS
MY158747A (en) Glucocorticoid receptor agonist comprising 2, 2, 4- trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group
DK1893589T3 (en) Substituted N-benzo [d] isoxazol-3-yl-amine derivatives as inhibitors of mGluR5, serotonin (5-HT) and norepinephrine receptors and their use in the preparation of drugs

Legal Events

Date Code Title Description
FA Abandonment or withdrawal